- Patent Title: Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation
-
Application No.: US14995679Application Date: 2016-01-14
-
Publication No.: US09696321B2Publication Date: 2017-07-04
- Inventor: Kosuke Kuroda , Hiroshi Morimatsu , Hidenori Wake , Shuji Mori , Masahiro Nishibori , Hideo Takahashi , Keyue Liu , Kiyoshi Teshigawara , Masakiyo Sakaguchi
- Applicant: National University Corporation Okayama University
- Applicant Address: JP Okayama
- Assignee: National University Corporation Okayama University
- Current Assignee: National University Corporation Okayama University
- Current Assignee Address: JP Okayama
- Agency: Kilyk & Bowersox, P.L.L.C.
- Priority: JP2012-129232 20120606
- Main IPC: A61K38/00
- IPC: A61K38/00 ; G01N33/68
Abstract:
The present invention provides a neutrophil activation regulator comprising a histidine-rich glycoprotein (HRG) for the treatment of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof. Further, the present invention provides methods for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation in a subject in need thereof, and methods for predicting the survival of a subject with systemic inflammatory response syndrome (SIRS), diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation, that comprise determining the blood level of histidine-rich glycoprotein in the subject.
Public/Granted literature
Information query
IPC分类:
